Ng Wang Yu Gary 4

What Happened Ng Wang Yu Gary, a director of Niagen Bioscience, was granted a derivative award covering 31,746 shares on June 24, 2026. The award shows a $0 acquisition price (no cash paid at grant) and is reported as an "A" (grant/award) transaction rather than a purchase or sale. Per the filing footnote, the option vests 100% on June 24, 2027.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely filing).
• Instrument: Derivative award (option) for 31,746 shares, reported acquisition price $0.00.
• Vesting: 100% vests on June 24, 2027 (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt.
• Transaction code: A = Grant/award/other acquisition.

Context This was a grant of options (a compensatory derivative award), not an open-market purchase or sale. Such awards typically vest over time and do not represent immediately tradable common shares until exercised and any vesting conditions are met. Awards are common forms of director/executive compensation and are not, by themselves, a clear buy or sell signal.